secwatch.observer — SEC 8-K summary
======================================

Issuer:     MeiraGTx Holdings plc (MGTX)
CIK:        0001735438
Form:       8-K
Filed at:   2022-03-10T23:59:59+00:00
Accession:  0001558370-22-003224
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MeiraGTx reports 2021 net loss of $79.6M; cash $137.7M; pipeline advances
-------------------------------------------------------------------------

- Net loss $79.6M ($1.80/share) vs $58.0M ($1.54/share) in 2020; license revenue rose to $37.7M from $15.6M.
- Cash and equivalents $137.7M at Dec 31, 2021; expects to fund operations through Q2 2023.
- Phase 3 Lumeos trial for XLRP enrolling; received $30M milestone from Janssen.
- Positive Phase 1 data for AAV-hAQP1 in xerostomia; Phase 2 start planned by end of 2022.
- R&D expenses $67.1M vs $33.9M, driven by ophthalmology, neurology, and manufacturing programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1735438/000155837022003224/0001558370-22-003224-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1735438/000155837022003224/mgtx-20220310x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-003224

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer